AG真人官方

Marex Group plc (MRX) 鈥� Schedule 13G/A (Amendment 1) filed 28 July 2025

A consortium of prior shareholders鈥擮cean Ring Jersey Co Ltd (Jersey), Ocean Trade Lux Co S.脿 r.l. (Luxembourg) and four related Trilantic Capital Partners vehicles鈥攏ow reports aggregate beneficial ownership of 0 ordinary shares, or 0.0 % of the outstanding class. All filers indicate no sole or shared voting or dispositive power. Item 5 confirms ownership has fallen below the 5 % reporting threshold; therefore the group is no longer a 鈥渞eporting person鈥� after this amendment.

Prior to disposal, the shares were held directly by Ocean Ring, a wholly-owned subsidiary of Ocean Trade, itself controlled by Trilantic Capital Partners IV (Europe) and co-investors. The filing contains no financial results, purchase price data or forward-looking statements; it solely updates beneficial ownership status.

Key takeaway for investors: A formerly significant private-equity-backed group has fully exited its equity position, potentially removing an overhang but also signalling that strategic investors have realised their investment.

Inozyme Pharma, Inc. (NASDAQ: INZY) filed Post-Effective Amendment No. 1 to deregister securities remaining under two previously effective shelf Registration Statements on Form S-3 (Nos. 333-258702 and 333-275364). The shelves collectively covered up to $500 million of common stock, preferred stock, debt, depositary shares, subscription rights, warrants and units. As of July 1, 2025, none of the registered securities remain available for sale.

The amendment follows the consummation of Inozyme鈥檚 merger with BioMarin Pharmaceutical Inc. Under the Agreement and Plan of Merger dated May 16, 2025, Incline Merger Sub, Inc. merged with and into Inozyme, making Inozyme a wholly-owned subsidiary of BioMarin as of July 1, 2025. Consequently, all outstanding offerings under the shelves were terminated and the company is removing any unsold securities from registration pursuant to its undertaking under Rule 415.

This filing is largely administrative, signaling the formal close-out of Inozyme鈥檚 capital-raising capability as a standalone public entity and completing one of the final SEC steps associated with the transaction.

On July 1, 2025, Director Richard J. Salute filed a Form 4 reporting that on June 30, 2025 he received 2,283 restricted shares of NewtekOne, Inc. (NEWT) common stock under the shareholder-approved 2023 Stock Incentive Plan. The award is coded 鈥淎鈥� (grant) at an indicated price of $10.95 per share and will vest 100 % after 12 months. Any dividends declared during the restricted period will be paid in additional common shares that follow the same vesting schedule. After this grant, Salute鈥檚 direct beneficial ownership increases to 41,505 shares. No derivative securities or open-market transactions were disclosed, and the filing was submitted solely by the reporting person.

NewtekOne, Inc. (NEWT) 鈥� Form 4 insider filing: Director Gregory L. Zink was granted 2,283 restricted shares of common stock on 30 June 2025 under the company鈥檚 2023 Stock Incentive Plan. The award vests 100% after 12 months; any dividends paid during the restriction period will be delivered in stock and will follow the same vesting schedule. The filing lists an indicated price of $10.95 and shows Zink鈥檚 total direct beneficial ownership rising to 36,207 shares following the grant. No derivative securities transactions were reported.

BioMarin Pharmaceutical Inc., through wholly-owned Incline Merger Sub, Inc., has completed its cash tender offer for all outstanding shares of Inozyme Pharma, Inc. (INZY) at $4.00 per share. The offer expired one minute after 11:59 p.m. ET on 30 June 2025 and was not extended. The paying agent confirmed that 45,455,118 shares, representing 69.8 % of the issued and outstanding shares, were validly tendered and not withdrawn, satisfying the minimum condition.

On 1 July 2025 the purchaser accepted all tendered shares for payment and immediately effected a short-form merger under DGCL 搂251(h), making Inozyme a wholly-owned subsidiary of BioMarin. Trading in INZY was halted and the shares were delisted from Nasdaq prior to the market open on 1 July 2025. BioMarin also intends to terminate Inozyme鈥檚 Exchange Act registration and suspend its SEC reporting obligations as promptly as practicable.

A press release detailing the completion of the offer and merger is filed as Exhibit (a)(5)(ix). Former Inozyme stockholders will receive the agreed $4.00 cash consideration, and the company will no longer operate as an independent public entity.

NewtekOne (NASDAQ:NEWT) filed an 8-K announcing the declaration of a quarterly dividend of $0.19 per share. The filing includes standard forward-looking statements and risk disclosures. The company furnished a press release dated June 25, 2025, which is included as Exhibit 99.1 to the filing.

Form 4 snapshot: On 06/20/2025 NewtekOne, Inc. (NEWT) Chairman & CEO Barry Sloane executed two open-market purchases of 1,000 shares each at $10.3923 and $10.3925, totaling 2,000 common shares.

After the transactions, Sloane鈥檚 direct ownership increases to 1,202,459 shares. No derivative securities were reported and no Rule 10b5-1 trading plan box was checked. The incremental buy represents less than 0.2 % of his existing stake but can signal management confidence in the stock.